A new report by HMA colleagues looks at policies, including new emergency regulations and temporary flexibilities, put in place during the COVID-19 pandemic.
HMA examines CMS Innovation Models over the past decade
June 14, 2021
A new issue brief and accompanying data set by HMA colleagues examines models implemented by the Centers for Medicare & Medicaid Services (CMS) Center for Medicare and Medicaid Innovation (The Innovation Center) over the past decade and provides evaluation of the findings.
HMA authors report examining future of COVID-19 Medicare regulation changes
May 25, 2021
A new Issue Brief, authored by Jennifer Podulka and Jon Blum, examines the many changes to Medicare regulations put in place during the COVID-19 pandemic. The brief, Which Medicare Changes Should Continue Beyond the COVID-19 Pandemic? Four Questions for Policymakers, tracks and categorizes the regulatory changes, describes the benefits and risks of the changes, and … Read More
Issue brief explores personal health record for children, youth, and families involved with child welfare in California
May 10, 2021
HMA Senior Consultant Suzanne Rabideau, Principals Heidi Arthur and Eileen Moscaritolo and Consultant Anh Pham recently developed the issue brief Exploration of a Personal Health Record for Children, Youth, and Families Involved with Child Welfare in CA for California’s Medicaid CalAIM Foster Care Model of Care Workgroup. The issue brief was developed to assist the … Read More
HMA publishes white paper “Moving Beyond COVID-19 Public Health Emergency Risk Corridors”
May 9, 2021
HMA has published a white paper identifying the appropriate, and inappropriate, uses of risk corridors in the context of Medicaid managed care capitation rate setting. The paper is timely due to the widespread use of risk corridors by states during the COVID-19 public health emergency (PHE) and the potential continuation of those risk corridors after … Read More
HMA contributes to NAM perspectives discussion paper ‘Guide for Future Directions for Addiction and OUD Treatment Ecosystem’
April 7, 2021
HMA Managing Directors R. Corey Waller, MD, MS, and Jean Glossa, MD, MBA, along with members of the Prevention, Treatment, and Recovery Working Group of the Action Collaborative on Countering the U.S. Opioid Epidemic, recently authored a new National Academy of Medicine Perspectives discussion paper calling for a long-term sustainable approach to preventing and managing … Read More
Youth needs assessment published
March 25, 2021
With a focus on the needs of young people in detention and correctional facilities, a team of Health Management Associates (HMA) colleagues completed an in-depth assessment designed to guide future planning and decision making around mental health services for youth.
Nursing home report highlights benefits of single resident rooms
March 23, 2021
The COVID-19 pandemic highlighted nursing home safety and infection control as critical public health issues. A new report authored by HMA colleagues found compelling evidence that single rooms in nursing homes have numerous benefits for both public health and residents’ experience. The authors conclude that transitioning from multi-resident rooms to single rooms should be a … Read More
2021 Medicare Advantage Supplemental Benefit Flexibilities: An Early Assessment of Adoption and Policy Opportunities for Expanded Access
January 13, 2021
The experts at Health Management Associates (HMA) have released Medicare Advantage Supplemental Benefit Flexibilities: An Early Assessment of Adoption and Policy Opportunities for Expanded Access. The white paper examines the factors contributing to a Medicare Advantage plan’s decision to offer or not offer newly available supplemental benefits and opportunities and challenges with adoption and implementation. … Read More
Three HMA clinicians author naltrexone formulations in correctional settings issue brief
January 13, 2021
HMA’s Donna Strugar-Fritsch, Shannon Robinson, MD and Scott Haga, PA-C, recently authored the issue brief, Naltrexone Formulations in Correctional Settings. This brief provides clinical, financial, and administrative information prisons and jails can use in deciding whether to keep detainees on extended release naltrexone (XR-NTX, or the brand Vivitrol) or switch them to oral naltrexone tablets … Read More